

REMARKS

The present amendment adds an Abstract of the Disclosure on a separate sheet and modifies the form only of the claims while eliminating use Claims 17 and 18 and discontinuing multiple dependency.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Benton S. Duffett Jr.
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: August 8, 2001

003300-816

Attachment to Preliminary Amendment dated August 8, 2001

Marked-up Claims 4 to 6, 8, 15, 16 and 19

4. (Amended) A monoclonal antibody according to [any one of the preceding claims] claim 1, wherein said serine proteinase is selected from the group consisting of activated protein C (APC), thrombin, coagulation factor X_a, trypsin, chymotrypsin, urokinase plasminogen activator (uPA), tissue type plasminogen activator (tPA), plasma kallikrein, factor XI_a, HGKI and prostatic specific antigen (PSA).

5. (Amended) A monoclonal antibody according to [any one of the preceding claims] claim 1, wherein said inhibitor is protein C inhibitor (PCI) or α_1 -antitrypsin.

6. (Amended) A method for preparation of a monoclonal antibody as defined in [any one of claims 1-5] claim 1, wherein an animal is immunised with a mixture of

- i) a complex between a serine proteinase and an inhibitor thereof, and
- ii) a cleaved form of said inhibitor, followed by screening for and isolation of said monoclonal antibody.

8. (Amended) A method for monitoring the activity of systems involving protein C inhibitor, wherein a monoclonal antibody as defined in [any one of claims 1-5] claim 1 is used in an immunoassay.

0990949-091001
"DOTS" 6469860

Attachment to Preliminary Amendment dated August 8, 2001

Marked-up Claims 4 to 6, 8, 15, 16 and 19

15. (Amended) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a monoclonal antibody according to [any one of claims 1-5] claim 1 is utilised.

16. (Amended) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a method according to [any one of claims 8-14] claim 8 is utilised.

19. (Amended) A kit for qualitative or quantitative determination of the activity of systems involving protein C inhibitor comprising a monoclonal antibody according to [any one of claims 1-5] claim 1.

0930949 091001
" 64606860
T00T60"

A1

Attachment to Preliminary Amendment dated August 8, 2001

Abstract of the Disclosure

The present invention relates to a monoclonal antibody suitable for monitoring the activity of systems involving protein C inhibitor, a method for preparation of said monoclonal antibody, a method for monitoring the activity of systems involving protein C inhibitor and a method for diagnosis of e.g., venous thrombosis, wherein said monoclonal antibody is utilised. Said monoclonal antibody is suitable for monitoring the activity of systems involving protein C inhibitor, and it has specific affinity for both i) a complex between a serine proteinase and an inhibitor thereof, and ii) a cleaved and uncomplexed form of said inhibitor, but has substantially no specific affinity for said inhibitor in its uncleaved and uncomplexed form; or a derivative thereof having the same biological activity.

003300-816-0001